A CRISPR-based gene editing therapy dramatically reduced levels of low-density lipoprotein, often called “bad cholesterol,” and triglycerides in patients with heart disease, a new study found.
Some researchers said that the treatment, developed by the biotech CRISPR Therapeutics and so…